Oral cannabis extracts in pediatric palliative care: retrospective review

Introduction and clinical context

The study Oral cannabis extracts in pediatric palliative care: retrospective review (PubMed · 2020) is part of the scientific research on the use of cannabinoids in pediatrics.

In pediatrics, medical cannabis is studied for spasticity in cerebral palsy, symptom control in oncology and palliative care, and complex motor disorders. Studies report an improvement in symptoms and quality of life in some cases, with an acceptable tolerability profile, but not always statistical superiority over placebo. Use in children requires careful indication, adjusted doses and specialized follow-up.

Understanding what science shows about the use of cannabinoids in pediatrics helps patients and healthcare professionals make safer, well-founded decisions, based on evidence rather than common sense.

Methodology and findings

This scientific review gathered and critically appraised the available literature on the topic. Retrospective review of the use of oral cannabis extracts in the pediatric palliative-care setting. As a synthesis of multiple studies, it offers a more robust picture than isolated reports, though it depends on the quality of the included works. For clinical practice, syntheses like this help calibrate expectations and support clinical decisions.

Mechanism of action and safety

In pediatrics, prescribing cannabinoids requires redoubled care: the developing brain is more sensitive to THC's effects, which is why CBD-rich formulations are favored in many indications. The mechanisms involve the modulation of neuronal excitability, spasticity and symptoms such as pain and nausea. Safety requires weight-adjusted doses, slow titration and monitoring of drowsiness, appetite changes and interactions. Use should be careful, led by a specialized team and integrated into overall pediatric care.

Regulation in Brazil (Anvisa)

In Brazil, access to cannabis products is regulated by Anvisa — mainly through RDC 660/2022 (patient import with a medical prescription) and the new manufacturing and import framework, RDC 1,015/2026. Any therapeutic use must start from an individualized medical assessment and prescription. This content is informative and scientific and does not replace the guidance of a healthcare professional.

This is informative content produced by Brazcann; for the full methodology and detailed results, consult the original publication (PubMed · 2020). Access to cannabis treatments must always occur through the regulated pathway, with a prescription and medical follow-up.

Frequently asked questions

Is cannabis used in children?

In specific indications and under specialized follow-up, with adjusted doses and careful indication.

Is there proof of efficacy?

There are reports of symptomatic improvement, but not always statistical superiority over placebo.

---

About this content

This page is a summary of scientific research published by third parties, provided for informational and educational purposes. Brazcann did not conduct, fund or sponsor the studies summarised here, and does not manufacture, sell, distribute or supply cannabis products.

This content is not a recommendation, therapeutic indication, prescription or medical advice, and does not replace assessment by a qualified professional. Study results do not guarantee individual efficacy, and publication of a study does not mean regulatory approval in Brazil.

Please consult the primary source cited on this page.

Last reviewed: 30/07/2026